Translate Bio, Inc. (NASDAQ:TBIO) Director Sells $1,134,680.00 in Stock

Translate Bio, Inc. (NASDAQ:TBIO) Director Owen Hughes sold 29,860 shares of the business’s stock in a transaction that occurred on Tuesday, September 14th. The stock was sold at an average price of $38.00, for a total transaction of $1,134,680.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of NASDAQ:TBIO opened at $37.36 on Wednesday. The stock has a 50-day simple moving average of $34.87 and a 200-day simple moving average of $25.36. The stock has a market capitalization of $2.82 billion, a P/E ratio of 66.71 and a beta of 0.99. Translate Bio, Inc. has a 1 year low of $11.91 and a 1 year high of $37.99.

Translate Bio (NASDAQ:TBIO) last issued its quarterly earnings data on Wednesday, August 4th. The company reported $0.21 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.44. The firm had revenue of $72.65 million during the quarter, compared to the consensus estimate of $38.23 million. Translate Bio had a return on equity of 1.50% and a net margin of 17.97%. Research analysts expect that Translate Bio, Inc. will post -0.6 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Hancock Whitney Corp lifted its holdings in shares of Translate Bio by 1.3% during the second quarter. Hancock Whitney Corp now owns 35,191 shares of the company’s stock valued at $969,000 after purchasing an additional 460 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Translate Bio by 0.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 70,606 shares of the company’s stock worth $1,944,000 after acquiring an additional 605 shares in the last quarter. Wilbanks Smith & Thomas Asset Management LLC lifted its stake in Translate Bio by 4.3% in the 1st quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 15,348 shares of the company’s stock worth $253,000 after acquiring an additional 638 shares in the last quarter. State of Wisconsin Investment Board lifted its stake in Translate Bio by 1.0% in the 1st quarter. State of Wisconsin Investment Board now owns 110,200 shares of the company’s stock worth $1,817,000 after acquiring an additional 1,100 shares in the last quarter. Finally, Swiss National Bank lifted its stake in Translate Bio by 1.2% in the 1st quarter. Swiss National Bank now owns 101,900 shares of the company’s stock worth $1,680,000 after acquiring an additional 1,200 shares in the last quarter. 88.84% of the stock is owned by institutional investors and hedge funds.

Several analysts have weighed in on the stock. Roth Capital dropped their target price on shares of Translate Bio from $45.00 to $38.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 3rd. Zacks Investment Research upgraded shares of Translate Bio from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Wednesday, August 4th. William Blair cut shares of Translate Bio from an “outperform” rating to a “market perform” rating in a research note on Tuesday, August 3rd. SVB Leerink lifted their price objective on shares of Translate Bio from $19.00 to $38.00 and gave the company a “market perform” rating in a research note on Tuesday, August 3rd. Finally, TheStreet upgraded shares of Translate Bio from a “d+” rating to a “c” rating in a research note on Thursday, May 27th. Seven analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $27.13.

About Translate Bio

Translate Bio, Inc engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T.

Recommended Story: Why do corrections happen?

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.